Dyne Therapeutics, Inc. (DYN) NASDAQ
18.16
+0.12(+0.67%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
18.16
+0.12(+0.67%)
Currency In USD
| Previous Close | 18.04 |
| Open | 18.04 |
| Day High | 19 |
| Day Low | 17.94 |
| 52-Week High | 25 |
| 52-Week Low | 8.06 |
| Volume | 1.95M |
| Average Volume | 2.13M |
| Market Cap | 3B |
| PE | -5.23 |
| EPS | -3.47 |
| Moving Average 50 Days | 17.73 |
| Moving Average 200 Days | 16.43 |
| Change | 0.12 |
Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 (DM1)
GlobeNewswire Inc.
Mar 08, 2026 10:01 PM GMT
- HARMONIA trial will assess multi-system efficacy, safety and tolerability of z-basivarsen in DM1 - - 48-week trial will enroll approximately 150 individuals, and first sites are now open for enrollment - - Primary endpoint is the five times sit to
Dyne Therapeutics Announces New Positive Cardiopulmonary Results from DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)
GlobeNewswire Inc.
Mar 08, 2026 10:00 PM GMT
- New analyses out to 24-months showed improvement in heart and lung function compared to expected declines in DMD natural history - - Data expand on previously reported results demonstrating that z-rostudirsen treatment led to sustained functional i
Dyne Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewswire Inc.
Feb 25, 2026 12:30 PM GMT
WALTHAM, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that ma